COMP <GO>
FLGT vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Fulgent Genetics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: FLGT 2
— MRK 9
■ METRIC PARITY
LAST: $20.62 (-4.89%) • MKT CAP: $596.5M
options-implied-move
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FLGT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FLGT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.60% | 74.80% | -34.20 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.80% | 20.70% | -27.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.82% | 3.42% | -24.24 | MRK | /fcf-yield <GO> |
| Operating Margin | -28.20% | 34.30% | -62.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | -18.80% | 28.10% | -46.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 13.80% | 1.30% | +12.50 | FLGT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.44 | 5.19 | -0.75 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.3 | 51.7 | +4.60 | FLGT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $596.5M | $361.02B | -$360.42B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FLGT REV | MRK REV | FLGT GROSS % | MRK GROSS % | FLGT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $322.7M | $65.01B | 40.6% | 74.8% | -$124.2M | $12.36B |
| FY 2024 | $283.5M | $64.17B | 37.8% | 76.3% | -$19.3M | $18.10B |
| FY 2023 | $289.2M | $60.12B | — | — | $27.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FLGT // BETA —
MRK // BETA 0.92